Preclinical safety assessment in therapeutic genome editing
Cell & Gene Therapy Insights 2023; 9(1), 203–205
Published: 10 March 2023
On February 23rd 2023, David McCall, Editor, Cell & Gene Therapy Insights, talked to Roberto Nitsch, Director of the Gene Therapy Safety at AstraZeneca, about his work in the space of genome editing nonclinical safety assessment and model development. This Viewpoint article is based on that interview.